Literature DB >> 19027460

Colon cancer in older adults.

Laura Raftery1, Hanna Kelly Sanoff, Richard Goldberg.   

Abstract

Colorectal cancer (CRC) is a common malignancy in the elderly. Randomized trials have demonstrated that adjuvant and palliative chemotherapy for CRC improves survival and quality of life. Unfortunately, there is a lack of evidence-based data about elderly patients to guide decisions regarding therapy. Clinical trials have generally excluded the vulnerable elderly population commonly seen in practice and included the robust elderly, who seem to benefit from chemotherapy as much as younger patients. The existing literature consists of pooled datasets from large studies and a few small dedicated trials on chemotherapy and its toxicity in elderly patients with CRC. We present illustrative data in this article and summarize our recommendations for managing the disease in elderly patients in a variety of clinical circumstances.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027460     DOI: 10.1053/j.seminoncol.2008.08.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

Review 1.  The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments.

Authors:  Angelina Pranteda; Valentina Piastra; Lorenzo Stramucci; Deborah Fratantonio; Gianluca Bossi
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

2.  Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells.

Authors:  Ying Shi; Xiao-Xiao Huang; Guo-Bin Chen; Ying Wang; Qiang Zhi; Yuan-Sheng Liu; Xiao-Ling Wu; Li-Fen Wang; Bing Yang; Chuan-Xing Xiao; Hui-Qin Xing; Jian-Lin Ren; Yin Xia; Bayasi Guleng
Journal:  Oncotarget       Date:  2016-07-26

3.  MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1.

Authors:  Hui Liu; Xin-Hua Cheng
Journal:  Oncotarget       Date:  2018-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.